QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Positive Results from Pulmonary Hypertension Clinical Study
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has released data from its HYPER-H21-3 human study. The company noted that data from its simulated pulmonary hypertension clinical study indicate positive safety and efficacy findings. Specifically, results show a tendency (p=0.1) during 15 minutes of simulated low levels of oxygen (hypoxia) for reduced pulmonary artery systolic pressure (“PASP”) with DehydraTECH-CBD treatment versus placebo. According to the announcement, PASP was significantly attenuated by about 5 mmHg or 41% overall (p=0.045) in male participants, which could indicate potential differences by sex in responsiveness to CBD treatment under hypoxic stress conditions. The…